ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 121 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $787,897 | +14.4% | 39,277 | +60.8% | 0.00% | – |
Q2 2023 | $688,888 | +100.0% | 24,420 | +22.0% | 0.00% | – |
Q1 2023 | $344,378 | +67.0% | 20,022 | +95.5% | 0.00% | – |
Q4 2022 | $206,213 | -77.6% | 10,239 | -75.9% | 0.00% | – |
Q3 2022 | $919,000 | +245.5% | 42,406 | +347.8% | 0.00% | – |
Q2 2022 | $266,000 | -64.0% | 9,470 | -40.8% | 0.00% | – |
Q1 2022 | $738,000 | -26.2% | 16,000 | +34.6% | 0.00% | – |
Q4 2021 | $1,000,000 | -43.1% | 11,889 | -64.0% | 0.00% | -100.0% |
Q2 2021 | $1,756,000 | +79.2% | 33,000 | +74.8% | 0.00% | – |
Q4 2020 | $980,000 | +57.1% | 18,876 | +45.3% | 0.00% | – |
Q2 2020 | $624,000 | – | 12,994 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |